Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs.
To examine the mechanisms of an angiotensin-converting enzyme (ACE) inhibitor-induced cough in perimenopausal and postmenopausal women, cough responses to aerosols of capsaicin and citric acid were examined in four groups of female guinea pigs treated orally with danazol (D) (an agent decreasing plasma estrogen levels), cilazapril (C) (an inhibitor of ACE), both danazol and cilazapril (C+D), or without either drug (control group) for 4 to 5 wk. Capsaicin caused dose-dependent increases in the number of coughs in all four groups. C or D alone shifted dose-response curves to capsaicin (from 10(-7) M to 10(-3) M) to lower concentrations compared with the control, and C+D further shifted them. Likewise, the number of coughs induced by citric acid (3 x 10(-1) M; 2 min) was highest in animals treated with C+D and significantly higher in animals treated with C or D than in the control group. Aerosols of a selective substance P (SP) receptor antagonist FK 888 (10(-5) M; 2 min) inhibited capsaicin-induced cough in all four groups, and dose-response curves to capsaicin did not differ significantly at any concentrations among the four groups in the presence of FK 888 (p > 0.10). D decreased cyclic AMP levels in the trachea, irrespective of the combination of C. A beta 2-adrenoceptor agonist, procaterol, which is thought to inhibit SP release by elevation of cyclic AMP in sensory nerves, dose-dependently inhibited the number of coughs induced by capsaicin (10(-3) M) in animals treated with D. The present study suggests that SP is a common mechanism mediating increases in the sensitivity of cough reflex induced by both ACE inhibition and a decrease in plasma estrogen levels, and the additive effects of the two events may explain the high incidence of cough during ACE inhibitor therapy in perimenopausal and postmenopausal women.
Ebihara
T
T
Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai, Japan.
Sekizawa
K
K
Ohrui
T
T
Nakazawa
H
H
Sasaki
H
H
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D002211:Capsaicin; D017315:Cilazapril / Q000494:pharmacology; D002951:Citrates; D019343:Citric Acid; D003371:Cough / Q000139:chemically induced*; D000242:Cyclic AMP / Q000378:metabolism; D003613:Danazol / Q000494:pharmacology*; D004151:Dipeptides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006168:Guinea Pigs; D007211:Indoles / Q000494:pharmacology; D017265:Procaterol / Q000494:pharmacology; D012018:Reflex / Q000187:drug effects*; D012737:Sex Factors; D013373:Substance P / Q000037:antagonists & inhibitors; D014132:Trachea / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002951:Citrates; D004151:Dipeptides; D004965:Estrogen Antagonists; D007211:Indoles; C078949:FK 888; D017315:Cilazapril; D019343:Citric Acid; D013373:Substance P; D000242:Cyclic AMP; D003613:Danazol; D002211:Capsaicin; D017265:Procaterol